ARROWHEAD PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Operations and Comprehensive (Loss) Income
(In thousands, except per share amounts)
| Three Months Ended March 31, | Six Months Ended March 31, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $— | $146,267 | $3,551 | $208,813 |
| Operating expenses: | ||||
| Research and development | 101,122 | 74,881 | 217,613 | 158,576 |
| General and administrative | 25,069 | 23,221 | 48,674 | 44,206 |
| Total operating expenses | 126,191 | 98,102 | 266,287 | 202,782 |
| Operating (loss) income | (126,191) | 48,165 | (262,736) | 6,031 |
| Other income (expense): | ||||
| Interest income | 6,250 | 4,560 | 9,052 | 7,242 |
| Interest expense | (7,244) | (5,057) | (12,611) | (7,906) |
| Other, net | 189 | 8 | 610 | 515 |
| Total other expense | (805) | (489) | (2,949) | (149) |
| (Loss) income before income tax (benefit) expense and noncontrolling interest | (126,996) | 47,676 | (265,685) | 5,882 |
| Income tax (benefit) expense | — | — | (3,313) | 17 |
| Net (loss) income including noncontrolling interest | (126,996) | 47,676 | $(262,372) | $5,865 |
| Net loss attributable to noncontrolling interest, net of tax | (1,696) | (999) | (4,208) | (1,485) |
| Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | $(125,300) | $48,675 | $(258,164) | $7,350 |
| Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||||
| Basic | $(1.02) | $0.46 | $(2.24) | $0.07 |
| Diluted | $(1.02) | $0.45 | $(2.24) | $0.07 |
| Weighted-average shares used in calculating | ||||
| Basic | 123,285 | 106,757 | 115,307 | 106,394 |
| Diluted | 123,285 | 108,143 | 115,307 | 107,893 |
| Other comprehensive (loss) income, net of tax: | ||||
| Change in unrealized losses on available-for-sale securities | 216 | — | 2,125 | — |
| Foreign currency translation adjustments | (56) | (74) | 2 | (196) |
| Comprehensive (loss) income | $(126,836) | $47,602 | $(260,245) | $5,669 |
Consolidated Statements of Stockholders’ Equity
(in thousands)
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Loss | AccumulatedDeficit | Non-controlling Interest | Totals | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2023 | 107,312 | $200 | $1,300,395 | $(3,222) | $(1,026,030) | $15,819 | $287,162 |
| Stock-based compensation | — | — | 19,694 | — | — | — | 19,694 |
| Exercise of stock options | 34 | — | 267 | — | — | — | 267 |
| Common stock - restricted stock units vesting | 154 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | 58 | — | — | 58 |
| Change in unrealized losses on available-for-sale securities | — | — | — | 1,909 | — | — | 1,909 |
| Net loss | — | — | — | — | (132,864) | (2,512) | (135,376) |
| Balance at December 31, 2023 | 107,500 | $200 | $1,320,356 | $(1,255) | $(1,158,894) | $13,307 | $173,714 |
| Stock-based compensation | — | — | 17,750 | — | — | — | 17,750 |
| Exercise of stock options | 120 | — | 1,512 | — | — | — | 1,512 |
| Common stock - restricted stock units vesting | 723 | 1 | (1) | — | — | — | — |
| Common stock issued, net of offering costs | 15,790 | 16 | 429,249 | — | — | — | 429,265 |
| Foreign currency translation adjustments | — | — | — | (56) | — | — | (56) |
| Change in unrealized losses on available-for-sale securities | — | — | — | 216 | — | — | 216 |
| Net loss | — | — | — | — | (125,300) | (1,696) | (126,996) |
| Balance at March 31, 2024 | 124,133 | $217 | $1,768,866 | $(1,095) | $(1,284,194) | $11,611 | $495,405 |
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Loss | AccumulatedDeficit | Non-controlling Interest | Totals | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2022 | 105,960 | $198 | $1,219,213 | $(136) | $(820,755) | $19,819 | $418,339 |
| Stock-based compensation | — | — | 19,390 | — | — | — | 19,390 |
| Exercise of stock options | 82 | — | 576 | — | — | — | 576 |
| Common stock - restricted stock units vesting | 98 | 1 | (1) | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | (122) | — | — | (122) |
| Net loss | — | — | — | — | (41,325) | (486) | (41,811) |
| Balance at December 31, 2022 | 106,140 | $199 | $1,239,178 | $(258) | $(862,080) | $19,333 | $396,372 |
| Stock-based compensation | — | — | 20,612 | — | — | — | 20,612 |
| Exercise of stock options | 64 | — | 520 | — | — | — | 520 |
| Common stock - restricted stock units vesting | 665 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | (74) | — | — | (74) |
| Net income | — | — | — | — | 48,675 | (999) | 47,676 |
| Balance at March 31, 2023 | 106,869 | $199 | $1,260,310 | $(332) | $(813,405) | $18,334 | $465,106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.